Sue Washer | Chief Executive Officer |
Jon Lieber | Chief Financial Officer |
Stephen Potter | Chief Business Officer |
Matt Feinsod | Executive Vice President, Global Clinical Strategy |
Matthew Luchini | BMO Capital |
Joe Pantginis | H.C. Wainwright |
Zegbeh Jallah | ROTH Capital Partners |
Yun Zhong | BTIG |
Kristen Kluska | Cantor Fitzgerald |
Jacques Villefranc | Stifel |
Yanan Zhu | Wells Fargo Securities |
Good afternoon and welcome to the AGTC Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call. Today’s call is being recorded.
Before we get started, I would like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its current and planned clinical trials. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of COVID-19 pandemic, and other risks described in the Risk Factors section of AGTC’s most recently filed Annual Report on Form 10-K and other periodic reports filed with the SEC. AGTC undertakes no obligation to update any forward-looking statements after the date of this call.